Sep 2026 quarter: consolidated revenue up 30.8% year on year, profit after tax turns positive
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 5,813.39 lakh versus Rs 4,444.92 lakh in the same quarter a year earlier, up 30.8%, while profit after tax was Rs 67.49 lakh versus a loss of Rs 56.03 lakh. EBITDA margin rose from 1.1% to 4.1%. Consolidated half-year revenue was Rs 10,169.65 lakh, profit after tax Rs 465.07 lakh and operating cash flow Rs 788.94 lakh. The review conclusion was unmodified.
Revenue growth, a higher operating margin and a return to profit support shareholders, but the small profit base may limit the stock-price impact.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.